Acute myeloid leukemia (AML) remains a challenge for both patients and clinicians. Despite improvements in our understanding of the disease and its underlying genetic factors, treatment outcomes still remain poor for many patients. The development of targeted therapies has shown promise in improving overall survival and patients’ quality of life. As these novel therapies continue to change treatment paradigms at a rapid pace, it is essential that oncologists and other clinicians are able to effectively incorporate these agents into practice to maximize patient outcomes. In this Clinical Toolkit, you will find recent treatment guidelines, clinical trial data on novel therapies, and research on biomarkers that impact treatment selection. A list of additional resources is provided to help improve the care of patients with AML.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.